Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESH 2017 | What are the drivers of leukemia?

Omar Abdel-Wahab • 12 Oct 2017
ESH 2017
Acute Myeloid Leukemia Chronic Lymphocytic Leukemia

Mutations can change the function of a protein and thus be the driver of diseases. In this video, Omar Abdel-Wahab, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses mutations in RNA splicing factors that have been identified in patients with leukemia, highlighting these exciting new therapeutic targets. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Omar Abdel-Wahab

The spliceosome mutations that can cause hematological malignancies
1:20
The spliceosome mutations that can cause hematological malignancies
Omar Abdel-Wahab • 5 Oct 2017
The importance of collaboration in AML research
0:53
The importance of collaboration in AML research
Omar Abdel-Wahab • 10 Oct 2017
Neomorphic mutations driving hematological cancers
1:14
Neomorphic mutations driving hematological cancers
Omar Abdel-Wahab • 10 Oct 2017
Therapeutics targeting splicing in hematological malignancies
0:52
Therapeutics targeting splicing in hematological malignancies
Omar Abdel-Wahab • 10 Oct 2017

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals